The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Roles of Periostin in Respiratory Disorders
Open accessAbstract
Periostin is a matricellular protein that has been implicated in many disease states. It interacts with multiple signaling cascades to modulate the expression of downstream genes that regulate cellular interactions within the extracellular matrix. This review focuses on the role of periostin in respiratory diseases, including asthma and idiopathic pulmonary fibrosis, and its potential to help guide treatment or assess prognosis. Epithelial injury is a common feature of many respiratory diseases, resulting in the secretion, among others, of periostin, which is subsequently involved in airway remodeling and other aspects of pulmonary pathophysiology. In asthma, periostin is recognized as a biomarker of type 2 inflammation; POSTN gene expression is up-regulated in bronchial epithelial cells by IL-13 and IL-4. Serum periostin has been evaluated for the identification of patients with increased clinical benefit from treatment with anti-IL-13 (lebrikizumab, tralokinumab) and anti-IgE (omalizumab) therapy and may be prognostic for increased risk of asthma exacerbations and progressive lung function decline. Furthermore, in asthma, periostin may regulate subepithelial fibrosis and mucus production and may serve as a systemic biomarker of eosinophilic airway inflammation. Periostin is also highly expressed in the lungs of patients with idiopathic pulmonary fibrosis, and its serum levels may predict clinical progression. Overall, periostin contributes to multiple pathogenic processes across respiratory diseases, and peripheral blood levels of periostin may have utility as a biomarker of treatment response and disease progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Woodruff, P. G., Boushey, H. A., Dolganov, G. M., Barker, C. S., Yang, Y. H., Donnelly, S., Ellwanger, A., Sidhu, S. S., Dao-Pick, T. P., Pantoja, C., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707413104 · Cited by 828 · cited 2×
“periostin expression to type 2 inflammation in asthma (21, 27, 32), its potential as a clinically validated biomarker to predict the response to treatments targeting type 2 cytokines is being investigated.”
Background
Cited by
Immunologic mechanisms in asthma
Boonpiyathad, T., Sözener, Z. C., Satitsuksanoa, P., & Akdis, C. A. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101333 · Cited by 489
Targeting cytokines to treat asthma and chronic obstructive pulmonary disease
Barnes, P. J. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0006-6 · Cited by 418
A phase 2 randomized controlled study of tralokinumab in subjects with idiopathic pulmonary fibrosis
Parker, J. M., Glaspole, I. N., Lancaster, L. H., Haddad, T. J., She, D., Roseti, S. L., Fiening, J. P., Grant, E. P., Kell, C. M., & Flaherty, K. R. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201704-0784oc · Cited by 129
Nonallergic rhinitis and lower airway disease
Rondón, C., Bogas, G., Barrionuevo, E., Blanca, M., Torres, M. J., & Campo, P. (2017) · Allergy · doi:10.1111/all.12988 · Cited by 74
The Usefulness of Biomarkers in Diagnosis of Asbestos-Induced Malignant Pleural Mesothelioma
Tanrıverdi, Z., Meteroglu, F., Yüce, H., Şenyiğit, A., Işcan, M., & Unüvar, S. (2021) · Human & Experimental Toxicology · doi:10.1177/09603271211017324 · Cited by 7
“Periostin combines with other extracellular matrix proteins to support the formation of collagen fibers, and has been associated with fibrotic diseases such as bronchial asthma, scleroderma and atopic dermatitis.(47) An autopsy of a patient with familial idiopathic pulmonary fibrosis, revealed periostin to be highly e…”
Background
Metadata
- Authors
- Izuhara, K., Conway, S. J., Moore, B. B., Matsumoto, H., Holweg, C. T. J., Matthews, J. G., & Arron, J. R.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-05-01
- Volume
- 193
- Issue
- 9
- Pages
- 949-956
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2233397884
- Cited by
- 189
- References
- 1
- FWCI
- 19.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.